Concepedia

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz, Mark Lakshmanan, Prem Pais, Jeffrey L. Probstfield, Jeffrey S. Riesmeyer, Matthew C. Riddle, Lars Rydén,

The Lancet · 2019 · 3K citations · 20 references

DOIFull text

Open access

Concepts

References

20

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

, , +13

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text

, , +17

Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate

Andrew S. Levey, Josef Coresh, Tom Greene et al. · Annals of Internal Medicine · 2006 · 5.8K citations

, , +17

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Marc A. Pfeffer, Brian Claggett, Rafael Díaz et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text

, , +17

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

, , +14